Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01278
|
|||||
| Drug Name |
Zolmitriptan
|
|||||
| Synonyms |
(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; AscoTop; AscoTop (TN); BW-311C90; Flezol; KS-5072; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zolmitriptane; Zolmitriptanum; Zomig; Zomig (TN); Zomig Nasal Spray; Zomig ZMT; Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; Zomig-ZMT; Zomigon; Zomigon (TN); Zomigoro (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Cluster headaches [ICD11:8A82] | Approved | [1] | |||
| Migraine with aura [ICD11:8A80.1] | Approved | [1] | ||||
| Migraine without aura [ICD11:8A80.0] | Approved | [1] | ||||
| Therapeutic Class |
Antimigraine Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H21N3O2
|
|||||
| Canonical SMILES |
CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
|
|||||
| InChI |
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
|
|||||
| InChIKey |
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
|
|||||
| CAS Number |
CAS 139264-17-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 287.36 | Topological Polar Surface Area | 57.4 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
2.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9427
,7847481
,7980917
,8187100
,11484392
,11488544
,11528684
,12014671
,14897880
,14922369
,26612872
,26680025
,26719749
,43118195
,46386880
,46386934
,46506452
,46530532
,49681573
,50730852
,57314155
,91011737
,92124588
,92308124
,92308640
,93166198
,96099961
,103346351
,103941674
,104179250
,104253285
,104321827
,117664449
,118855343
,124636835
,124757406
,124801240
,125164210
,126656630
,126667001
,129386325
,135017989
,135651366
,135692210
,135693782
,136974858
,137171693
,142742126
,144076376
,144205008
|
|||||
| ChEBI ID |
ChEBI:10124
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Zolmitriptan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41. | |||||
| 3 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.